If you continue to have this issue please contact [email protected]. Adults receiving tirzepatide in the SURPASS trials had significant decreases in urine albumin-to-creatinine ratio.
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback